Table of Contents
Chromatography Research International
Volume 2011 (2011), Article ID 256812, 10 pages
http://dx.doi.org/10.4061/2011/256812
Research Article

Stress Degradation Behavior of Paliperidone, an Antipsychotic Drug, and Development of Suitable Stability-Indicating RP-LC Method

1Department of Research and Development, Megafine Pharma (P) Ltd., Nashik 422 202, India
2Department of Chemistry, Deogiri College, Aurangabad 431 004, India

Received 9 February 2011; Accepted 5 April 2011

Academic Editor: Wenkui Li

Copyright © 2011 Sanjay A. Jadhav et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Schotte, P. F. M. Janssen, W. Gommeren et al., “Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding,” Psychopharmacology, vol. 124, no. 1-2, pp. 57–73, 1996. View at Google Scholar
  2. A. A. H. P. Megens and F. H. L. Awouters, “In vivo pharmacological profile of 9-hydroxyrisperidone, the major metabolite of the novel antipsychotic risperidone,” Drug Development Research, vol. 33, no. 4, pp. 399–412, 1994. View at Google Scholar
  3. N. Yasui-Furukori, M. Hidestrand, E. Spina, G. Facciola, M. G. Scordo, and G. Tybring, “Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes,” The American Society for Pharmacology and Experimental Therapeutics, vol. 29, no. 10, pp. 1263–1268, 2001. View at Google Scholar
  4. S. Tianmei, S. Liang, L. Yi, S. Yun'Ai, G. Chunmei, and Z. Hongyan, “Single-dose pharmacokinetics of paliperidone extended release tablets in healthy Chinese subjects,” Human Psychopharmacology: Clinical and Experimental, vol. 25, no. 5, pp. 404–409, 2010. View at Google Scholar
  5. M. P. Corena-McLeod, A. Oliveros, C. Charlesworth et al., “Paliperidone as a mood stabilizer: a pre-frontal cortex synaptoneurosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression,” Brain Research, vol. 1233, pp. 8–9, 2008. View at Google Scholar
  6. G. Marchese, B. Pittau, G. Casu et al., “A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats,” European Psychiatry, vol. 25, no. 2, pp. 92–100, 2010. View at Google Scholar
  7. R. Arakawa, H. Ito, A. Takano et al., “Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia,” Psychopharmacology, vol. 197, no. 2, pp. 229–235, 2008. View at Google Scholar
  8. Product Monograph, “Paliperidone, Extended release tablets 3 mg, 6 mg and 9 mg, http://www.janssen-ortho.com/JOI/pdf_files/Invega_E.pdf.
  9. M. Vermeir, I. Naessens, B. Remmerie et al., “Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans,” The American Society for Pharmacology and Experimental Therapeutics, vol. 36, no. 4, pp. 769–779, 2008. View at Google Scholar
  10. R. B. Patel, M. R. Patel, K. K. Bhatt, and B. G. Patel, “HPTLC method development and validation: quantification of paliperidone in formulations and in vitro release study,” Analytical Methods, vol. 2, pp. 525–531, 2010. View at Google Scholar
  11. B. Cabovska, S. L. Cox, and A. A. Vinks, “Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS,” Journal of Chromatography B, vol. 832, no. 1-2, pp. 497–504, 2007. View at Google Scholar
  12. R. Woestenborghs, W. Lorreyne, F. Van Rompaey, and J. Heykants, “Determination of risperidone and 9-hydroxyrisperidone in plasma, urine and animal tissues by high-performance liquid chromatography,” Journal of Chromatography, vol. 583, no. 2, pp. 223–230, 1992. View at Google Scholar
  13. “Impurities in new drug substances,” in Proceedings of the International Federation of Pharmaceutical Manufactures & Associations (IFPMA '06), International Conference on Harmonization (ICH), Geneva, Switzerland, October 2006, Methodology Q3A(R2).
  14. “Good manufacturing practice guide for active pharmaceutical ingredients,” in Proceedings of the International Federation of Pharmaceutical Manufactures & Associations (IFPMA '05), International Conference on Harmonization (ICH), Geneva, Switzerland, November 2005, Methodology Q7A.
  15. The United States Pharmacopeia, Validation of Compendial Methods, section 1225, The United States Pharmacopeia (USP), Rockville, Md, USA, 32nd edition, 2009.
  16. “Validation of analytical procedure,” in Proceedings of the International Federation of Pharmaceutical Manufactures & Associations (IFPMA '96), International Conference on Harmonization (ICH), Geneva, Switzerland, November 1996, Methodology Q2(R1).
  17. J. Ruan, P. Tattersall, R. Lozano, and P. Shah, “The role of forced degradation studies in stability indicating HPLC method development,” American Pharmaceutical Review, vol. 9, no. 1, pp. 46–53, 2006. View at Google Scholar
  18. M. Bakshi and S. Singh, “Development of validated stability-indicating assay methods-critical review,” Journal of Pharmaceutical and Biomedical Analysis, vol. 28, no. 6, pp. 1011–1040, 2002. View at Google Scholar
  19. H. C. Juan and C. M. Noelia, “Process to prepare paliperidone and intermediates thereof,” PCT Pat., WO 2009/144288 A1, 2009.
  20. R. L. Snyder, J. Kirkland, and L. Glajch, Practical LC Method Development, Jonh Wiley & Sons, Hoboken, NY, USA, 1997.
  21. R. LoBrutto, A. Jones, Y. V. Kazakevich, and H. M. McNair, “Effect of the eluent pH and acidic modifiers in high-performance liquid chromatography retention of basic analytes,” Journal of Chromatography A, vol. 913, no. 1-2, pp. 173–187, 2001. View at Google Scholar